ストックスクリーナーアプリを入手
193.40
5.19%
9.54
前日終値:
$183.86
開ける：
$189.52
24時間の取引高:
1.59M
Relative Volume:
0.80
時価総額：
$299.93B
収益：
$60.48B
当期純損益:
$10.40B
株価収益率:
58.08
EPS:
3.3297
ネットキャッシュフロー:
$8.05B
1週間 パフォーマンス:
+4.16%
1か月 パフォーマンス:
+8.99%
6か月 パフォーマンス:
+111.21%
1年 パフォーマンス:
+171.90%
1日の値動き範囲:
$189.17
$196.41
1週間の範囲:
$183.49
$196.41
52週間の値動き範囲:
$68.61
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
193.40 | 294.07B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,207.76 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
260.71 | 611.36B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
259.29 | 444.60B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
127.88 | 317.37B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
158.84 | 299.04B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-27 | 開始されました | Citigroup | Buy |
| 2025-10-27 | 再開されました | Jefferies | Buy |
| 2025-10-16 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 開始されました | Exane BNP Paribas | Outperform |
| 2025-02-13 | アップグレード | UBS | Neutral → Buy |
| 2025-02-12 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-20 | アップグレード | UBS | Sell → Neutral |
| 2024-11-06 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-09-13 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-04-16 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-02-08 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-16 | 再開されました | UBS | Sell |
| 2024-01-03 | ダウングレード | Jefferies | Buy → Hold |
| 2023-12-18 | 開始されました | HSBC Securities | Buy |
| 2023-09-25 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-07-12 | アップグレード | UBS | Neutral → Buy |
| 2023-07-05 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-04-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2022-09-15 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | アップグレード | Argus | Hold → Buy |
| 2022-06-14 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-11 | アップグレード | DZ Bank | Sell → Hold |
| 2021-12-07 | ダウングレード | Jefferies | Buy → Hold |
| 2021-08-12 | 再開されました | JP Morgan | Overweight |
| 2021-04-12 | ダウングレード | Argus | Buy → Hold |
| 2021-03-16 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | アップグレード | UBS | Neutral → Buy |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-12-07 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | アップグレード | UBS | Sell → Neutral |
| 2020-11-11 | アップグレード | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2019-11-22 | 開始されました | SVB Leerink | Outperform |
| 2019-10-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-02 | ダウングレード | UBS | Neutral → Sell |
| 2019-02-05 | 開始されました | Exane BNP Paribas | Outperform |
| 2019-01-25 | アップグレード | Shore Capital | Hold → Buy |
| 2018-12-11 | 再開されました | Jefferies | Hold |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-08-16 | ダウングレード | Jefferies | Buy → Hold |
| 2018-03-19 | アップグレード | Jefferies | Hold → Buy |
| 2018-02-06 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-05 | 繰り返されました | Bernstein | Outperform |
| 2018-01-18 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2017-12-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-10-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | アップグレード | Bernstein | Mkt Perform → Outperform |
すべてを表示
Astrazeneca Plc (AZN) 最新ニュース
China's CSPC Pharmaceutical Group to partner with AstraZeneca for renal disease drug - marketscreener.com
Abbisko Therapeutics Partners with AstraZeneca on Lung Cancer Th - GuruFocus
Abbisko teams with AstraZeneca on lung cancer trial after China IND clearance - Stock Titan
Why Astrazeneca (AZN) Dipped More Than Broader Market Today - Yahoo Finance
AstraZeneca PLC (AZN) Shares Fall 3.0% -- What GF Score of 76 Te - GuruFocus
AstraZeneca PLC Stock (AZN) Moved Down by 3.02% on Jul 1: What Investors Need To Know - TradingKey
AstraZeneca plc focuses on long-term growth as global pipeline expands - AD HOC NEWS
AstraZeneca admits 14,784 shares to London Stock Exchange - Investing.com
AstraZeneca PLC outlines long-term growth strategy as global drug portfolio expands - AD HOC NEWS
AstraZeneca admits 14,784 shares to London Stock Exchange By Investing.com - Investing.com Canada
AstraZeneca (NYSE: AZN) adds 14,784 employee scheme shares - Stock Titan
AstraZeneca (AZN) reports 1.55B total voting rights as of June 2026 - Stock Titan
REGAstraZeneca PLCAdmission of Further Securities to Trading - TradingView
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors (Revised) - TradingView
ASTRAZENECA : Goldman Sachs reaffirms its Buy rating - marketscreener.com
BofA Forecasts In-line Q2 Sales, EPS for AstraZeneca; Buy Rating Maintained - marketscreener.com
Price to earnings forward of AstraZeneca PLC – SWB:ZEG - TradingView
ETFs Investing in AstraZeneca PLC Stocks - TradingView
AstraZeneca slides Tuesday, underperforms market - MarketWatch
AstraZenecaEnhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours - marketscreener.com
AstraZeneca PLC strengthened by Enhertu EU approval. JP Morgan reiterates buy rating on the stock - AD HOC NEWS
ASTRAZENECA : Sell rating from Deutsche Bank - marketscreener.com
RB Capital Management, LLC's AstraZeneca PLC(AZN) Holding History - GuruFocus
ASTRAZENECA : Receives a Buy rating from JP Morgan - marketscreener.com
AstraZeneca To Pay $34M In Texas Kickbacks Settlement - Law360
AstraZeneca Details Bone Health Data For Strensiq Successor - insights.citeline.com
AstraZeneca Advances Rare Bone Disease Pipeline While Enhertu Expands In Europe - Benzinga
Astrazeneca plc Datroway Recommends for Approval in EU for TNBC - marketscreener.com
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors - TradingView
EU clears AstraZeneca (AZN) and Daiichi Sankyo’s Enhertu for HER2+ solid tumours - Stock Titan
AstraZeneca, Daiichi Sankyo Win EU Approval for Enhertu in HER2-positive Solid Tumors - marketscreener.com
AstraZeneca's Datroway and Enhertu candidates receive EU approval - Sharecast.com
AstraZeneca and Daiichi Sankyo’s Datroway recommended for EU approval in metastatic TNBC - DirectorsTalk Interviews
Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours - AstraZeneca
AstraZeneca’s Datroway gets EU panel backing for breast cancer By Investing.com - Investing.com UK
AZN Stock Quote Price and Forecast - CNN
Price to sales forward of AstraZeneca PLC – LSE:AZN - TradingView
AstraZeneca PLC AZN Q3 2025 Earnings Call Dallas Cowboys Schedule 2026 (4z9l16BTZU) - Mshale
Price to sales forward of AstraZeneca PLC ADR – BCBA:AZN.CI - TradingView
AstraZeneca highlights long-term oncology pipeline, shares supported by solid S&P 500 presence - Ad-hoc-news.de
AstraZeneca focuses on long-term oncology strategy, shares anchored in the FTSE 100 - Ad-hoc-news.de
The Breztri Aerosphere from AstraZeneca plctriple therapy aims at severe COPD - Ad-hoc-news.de
AstraZeneca cautious after EU panel vote, shares reflect Tavneos setback - Ad-hoc-news.de
AstraZeneca climbs Friday, outperforms market - MarketWatch
Why Did AstraZeneca (AZN) Stock Dip More Than the Market Today - Kavout | AI
Could This Clinical Milestone Reshape AstraZeneca’s (LSE:AZN) Future? - Kalkine Media
Daiichi Sankyo and AstraZeneca Announce Datroway Recommends for Approval in EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy - marketscreener.com
Jefferies names AstraZeneca a top pick ahead of pivotal heart drug readout - Yahoo Finance
AstraZeneca updates on pipeline and AI efforts, shares tracked by analysts - Ad-hoc-news.de
AstraZeneca's, Daiichi's Datroway recommended for further EU approval - London South East
AstraZeneca : Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy - marketscreener.com
Astrazeneca Plc (AZN) 財務データ
収益
当期純利益
現金流量
EPS
3.11%
大文字化:
|
ボリューム (24 時間):